Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Epilepsy Behav. 2013 Apr 5;28(2):243–248. doi: 10.1016/j.yebeh.2013.02.029

Table 1.

Ezogabine effects on CSD-induced activation of meningeal nociceptors

Increased activity
Decreased activity
Experimental group C-fibers Aδ-fibers % C-fibers Aδ-fibers %
Preemptive design (ezogabine given 2 min after CSD) 4 2 40% 4 5 60%
Preemptive design – control I (vehicle given 2 min after CSD) 1 2 50% 3 0 50%
Prophylactic design (ezogabine given 60 min before CSD) 1 0 8% 6 6 92%
Drug effect – control II 0 0 4 6
Spontaneous activity before CSD 0.94±0.34 0.24±0.12 0.83±0.22 0.49±0.16
Spontaneous activity after CSD 1.76±0.55 0.53±0.20 0.61±0.17 0.33±0.11
HHS Vulnerability Disclosure